Paricalcitol-D6 |
| Catalog No.GC36854 |
Paricalcitol-d6 is the deuterium labeled Paricalcitol.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2070009-67-3
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Paricalcitol-D6 is the deuterated form of Paricalcitol(Zemplar), which is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure. IC50 value:Target: Vd analogChemically, it is 19-nor-1,25-(OH)2-vitamin D2 or 19-nor-1,25-dihydroxyvitamin D2, being an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2.
[1]. Martinez-Moreno JM, Mu•oz-Casta•eda JR, Herencia C, Montes de Oca A, Estepa JC, Canalejo R, Rodriguez-Ortiz ME, Perez-Martinez P, Aguilera-Tejero E, Canalejo A, Rodriguez M, Almaden Y.In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation.Am J Physiol Renal Physiol. 2012 Aug 8. [2]. Ari E, Kedrah AE, Alahdab Y, Bulut G, Eren Z, Baytekin O, Odabasi D.Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model.Br J Radiol. 2012 Aug;85(1016):1038-43. [3]. Meems LM, Cannon MV, Mahmud H, Voors AA, van Gilst WH, SilljÉ HH, Ruifrok WP, de Boer RA.The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload.J Steroid Biochem Mol Biol. 2012 Jul 16;132(3-5):282-289. [4]. Blanco-GarcÍa R, Bravo-LÓpez JJ, Moreiras-Plaza M, NÁjera-de la Garza W, Cossio-Annibar C, Beato-Coo L, RodrÍguez-Goyanes G.Microalbuminuria, another use for paricalcitol• Our experience in advanced chronic kidney disease.Nefrologia. 2012 May 14;32(3):401-2. doi: 10.3265/Nefrologia.pre2012.Feb.11378. [5]. Piao SG, Song JC, Lim SW, Chung BH, Choi BS, Yang CW.Protective effect of paricalcitol on cyclosporine-induced renal injury in rats.Transplant Proc. 2012 Apr;44(3):642-5.
| Cas No. | 2070009-67-3 | SDF | |
| Canonical SMILES | C[C@]([C@@H]([C@@H](/C=C/[C@@H](C(C([2H])([2H])[2H])(C([2H])([2H])[2H])O)C)C)CC1)(CCC/2)[C@@]1(C2=C\C=C3C[C@H](C[C@@H](C/3)O)O)[H] | ||
| Formula | C27H38D6O3 | M.Wt | 422.67 |
| Solubility | DMSO : 100 mg/mL (236.59 mM; Need ultrasonic); DMSO : 100 mg/mL (236.59 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3659 mL | 11.8296 mL | 23.6591 mL |
| 5 mM | 0.4732 mL | 2.3659 mL | 4.7318 mL |
| 10 mM | 0.2366 mL | 1.183 mL | 2.3659 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *